| 主权项 |
1. A method of determining the risk of metastasis of prostate cancer in a human subject who has or had prostate cancer, the method comprising
(a) obtaining a prostate sample from the subject, (b) determining the number of copies per cell of at least 12 genes and/or genomic regions of a metastatic gene signature set, wherein the metastatic gene signature set consists of the PPP3CC genomic region, the SLCO5A1 genomic region, the SLC7A5 genomic region, the SLC7A2 genomic region, the CRISPLD2 genomic region, the CDH13 gene, the CDH8 gene, the CDH2 gene, the ASAH1 genomic region, the KCNB2 genomic region, the KCNH4 genomic region, the CTD8 gene, the JPH1 genomic region, the MEST genomic region, the NCALD genomic region, the COL19A1 gene, the MAP3K7 genomic region, the YWHAG gene, the NOL4 genomic region, and the ENOX1 gene, (c) determining alternations in the number of copies per cell for each of the at least 12 genes and/or genomic regions as compared to the number of copies per cell in non-cancer cells, and (d) determining the risk of prostate cancer metastasis based on the copy number alternations (CNAs) determined in step (c). |
